Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

SIMPONI ARIA® (golimumab)

Medical Information

+ Save link

Administration of SIMPONI ARIA at Doses Greater than 2 mg/kg in Adult Patients with Active Psoriatic Arthritis

Last Updated: 11/21/2024

SUMMARY

SIMPONI ARIA is indicated for the treatment of active psoriatic arthritis (PsA) in patients 2 years of age and older.¹
In adults with active PsA, the SIMPONI ARIA dosage regimen is 2 mg per kg given as an intravenous (IV) infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter. Follow the dilution and administration instructions for SIMPONI ARIA.¹
There is no data available regarding the administration of SIMPONI ARIA at doses greater than 2 mg/kg in adult patients with active PsA.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) conducted on 22 September 2024 did not identify any relevant citations pertaining to this topic.

References

Show

1	SIMPONI ARIA (golimumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc;https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SIMPONI+ARIA-pi.pdf